Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
These 2 Biotech Stocks Are Set to Soar
06:45am, Friday, 13'th Sep 2024
Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
12:38pm, Friday, 06'th Sep 2024
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
08:30am, Friday, 30'th Aug 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Bull Signal Flashing for Sarepta Therapeutics Stock
01:43pm, Monday, 19'th Aug 2024
After touching a nearly four-year high of $173.25 on June 21, shares of biotech firm Sarepta Therapeutics Inc (NASDAQ:SRPT) steadily worked lower on the charts, touching a more than two-month low o
Biotech Stock Flashing Bull Signal
02:39pm, Wednesday, 14'th Aug 2024
Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however
2 Biotech Stocks to Buy Hand Over Fist in August
09:30am, Monday, 12'th Aug 2024
Vertex's newest approval and late-stage pipeline should yield stronger financial results. Smaller biotech Sarepta Therapeutics continues to innovate in its core therapeutic area.
Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
10:36am, Friday, 09'th Aug 2024
Sarepta Therapeutics (SRPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
08:50am, Thursday, 08'th Aug 2024
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations.
7 Biotech Stocks to Buy for Their Game-Changing Potential
06:00am, Thursday, 08'th Aug 2024
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one.
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
07:00pm, Wednesday, 07'th Aug 2024
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metri
3 Genomics Stocks That May Transform Personalized Medicine
10:45am, Tuesday, 06'th Aug 2024
When the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the gene
What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
01:01pm, Monday, 05'th Aug 2024
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Biotech Stocks to Bet On Bright Industry Prospects
10:45am, Monday, 29'th Jul 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, S
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
06:08pm, Wednesday, 24'th Jul 2024
Sarepta Therapeutics, Inc. is a leader in DMD treatment, with recent FDA approval for SRP-9001 gene therapy across all age groups. Despite a recent stock pullback, the company reported strong revenue
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
10:56am, Friday, 19'th Jul 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable,
